219 related articles for article (PubMed ID: 27109020)
1. Epidrugs in the Immunotherapy of Cutaneous and Uveal Melanoma.
Venza M; Visalli M; Catalano T; Beninati C; Teti D; Venza I
Anticancer Agents Med Chem; 2017; 17(2):190-205. PubMed ID: 27109020
[TBL] [Abstract][Full Text] [Related]
2. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
3. Update on Metastatic Uveal Melanoma: Progress and Challenges.
Spagnolo F; Picasso V; Spano L; Tanda E; Venzano C; Queirolo P
BioDrugs; 2016 Jun; 30(3):161-72. PubMed ID: 27000042
[TBL] [Abstract][Full Text] [Related]
4. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
5. Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma.
Herlihy N; Dogrusöz M; van Essen TH; Harbour JW; van der Velden PA; van Eggermond MC; Haasnoot GW; van den Elsen PJ; Jager MJ
Invest Ophthalmol Vis Sci; 2015 Jan; 56(3):1447-58. PubMed ID: 25593028
[TBL] [Abstract][Full Text] [Related]
6. Identification of molecular subtyping system and four-gene prognostic signature with immune-related genes for uveal melanoma.
Xia F; Yu Z; Deng A; Gao G
Exp Biol Med (Maywood); 2022 Feb; 247(3):246-262. PubMed ID: 34743576
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma.
Venza M; Visalli M; Biondo C; Lentini M; Catalano T; Teti D; Venza I
Biochim Biophys Acta; 2015 Mar; 1849(3):247-56. PubMed ID: 25497382
[TBL] [Abstract][Full Text] [Related]
8. Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis.
Venza M; Visalli M; Beninati C; Biondo C; Teti D; Venza I
Anticancer Agents Med Chem; 2016; 16(5):528-38. PubMed ID: 26234362
[TBL] [Abstract][Full Text] [Related]
9. Role of Epigenetics in Uveal Melanoma.
Li Y; Jia R; Ge S
Int J Biol Sci; 2017; 13(4):426-433. PubMed ID: 28529451
[TBL] [Abstract][Full Text] [Related]
10. Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression.
García-Mulero S; Alonso MH; Del Carpio LP; Sanz-Pamplona R; Piulats JM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800878
[TBL] [Abstract][Full Text] [Related]
11. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma.
Chen X; He D; Dong XD; Dong F; Wang J; Wang L; Tang J; Hu DN; Yan D; Tu L
Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):2248-56. PubMed ID: 23404119
[TBL] [Abstract][Full Text] [Related]
13. High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines.
Hurks HM; Metzelaar-Blok JA; Mulder A; Claas FH; Jager MJ
Int J Cancer; 2000 Mar; 85(5):697-702. PubMed ID: 10699951
[TBL] [Abstract][Full Text] [Related]
14. Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients.
Maat W; van der Slik AR; Verhoeven DH; Alizadeh BZ; Ly LV; Verduijn W; Luyten GP; Mulder A; van Hall T; Koning F; Jager MJ; van Bergen J
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2888-95. PubMed ID: 19234348
[TBL] [Abstract][Full Text] [Related]
15. A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma.
Holling TM; Bergevoet MW; Wilson L; Van Eggermond MC; Schooten E; Steenbergen RD; Snijders PJ; Jager MJ; Van den Elsen PJ
J Immunol; 2007 Oct; 179(8):5317-25. PubMed ID: 17911618
[TBL] [Abstract][Full Text] [Related]
16. HLA antigen expression on uveal melanoma cells in vivo and in vitro.
de Waard-Siebinga I; Kool J; Jager MJ
Hum Immunol; 1995 Oct; 44(2):111-7. PubMed ID: 8847229
[TBL] [Abstract][Full Text] [Related]
17. Major histocompatibility antigens and antigen-processing molecules in uveal melanoma.
Krishnakumar S; Abhyankar D; Sundaram AL; Pushparaj V; Shanmugam MP; Biswas J
Clin Cancer Res; 2003 Sep; 9(11):4159-64. PubMed ID: 14519640
[TBL] [Abstract][Full Text] [Related]
18. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.
Chang CC; Pirozzi G; Wen SH; Chung IH; Chiu BL; Errico S; Luongo M; Lombardi ML; Ferrone S
J Biol Chem; 2015 Oct; 290(44):26562-75. PubMed ID: 26381407
[TBL] [Abstract][Full Text] [Related]
19. Targeting Epigenetic Modifications in Uveal Melanoma.
Chokhachi Baradaran P; Kozovska Z; Furdova A; Smolkova B
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32726977
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of uveal melanoma.
Bosch JJ
Dev Ophthalmol; 2012; 49():137-149. PubMed ID: 22042018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
